Japan · Delayed Price · Currency is JPY Sawai Group Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profits grew year-over-year, driven by higher sales and improved product value, while net income was boosted by a one-time gain from the U.S. business sale. FY 2025 guidance anticipates continued revenue and profit growth, despite cost pressures and industry reforms.
-
Revenue rose 6.7% year-on-year, but core operating profit fell 3.6% while operating profit surged due to the absence of litigation provisions. FY 2026 forecasts call for revenue and profit growth, with strong new product sales and increased production capacity.
-
Revenue and profits grew year-over-year, aided by a U.S. affiliate share sale and improved unit prices. The outlook targets further profit growth via new launches and cost controls, while a major share buyback and dividend hike were announced.
-
Revenue grew 12.5% year-over-year, but operating profit fell 27.4% due to a patent settlement. Core operating profit rose 9.5%, and full-year guidance was revised as production targets became harder to achieve.
Fiscal Year 2024
-
The new medium-term plan aims to expand domestic generics market share, boost production capacity, and invest in growth areas like digital health and overseas markets. Financial targets include JPY 220 billion revenue and improved capital efficiency, with strong focus on sustainability and governance.